GeneDx Holdings Corp. $WGS Shares Sold by Calamos Advisors LLC

Calamos Advisors LLC reduced its holdings in GeneDx Holdings Corp. (NASDAQ:WGS) by 22.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 44,575 shares of the company’s stock after selling 12,767 shares during the quarter. Calamos Advisors LLC owned 0.16% of GeneDx worth $4,115,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. bought a new position in shares of GeneDx in the first quarter valued at approximately $44,614,000. William Blair Investment Management LLC lifted its position in GeneDx by 37.2% in the second quarter. William Blair Investment Management LLC now owns 1,631,402 shares of the company’s stock worth $150,595,000 after purchasing an additional 442,414 shares during the period. Alliancebernstein L.P. boosted its stake in GeneDx by 3,054.5% during the 1st quarter. Alliancebernstein L.P. now owns 436,900 shares of the company’s stock valued at $38,694,000 after purchasing an additional 423,050 shares in the last quarter. Jennison Associates LLC increased its position in shares of GeneDx by 6,163.1% during the 2nd quarter. Jennison Associates LLC now owns 397,896 shares of the company’s stock valued at $36,730,000 after purchasing an additional 391,543 shares during the period. Finally, Wellington Management Group LLP increased its position in shares of GeneDx by 202.3% during the 1st quarter. Wellington Management Group LLP now owns 425,647 shares of the company’s stock valued at $37,697,000 after purchasing an additional 284,855 shares during the period. Institutional investors and hedge funds own 61.72% of the company’s stock.

GeneDx Stock Down 4.5%

Shares of GeneDx stock opened at $130.35 on Friday. GeneDx Holdings Corp. has a 12-month low of $55.17 and a 12-month high of $147.71. The company has a quick ratio of 2.59, a current ratio of 2.71 and a debt-to-equity ratio of 0.18. The stock has a 50 day moving average price of $126.10 and a two-hundred day moving average price of $101.34. The stock has a market capitalization of $3.77 billion, a P/E ratio of 1,448.33 and a beta of 2.01.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings results on Tuesday, October 28th. The company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.21. The company had revenue of $116.74 million for the quarter, compared to the consensus estimate of $104.33 million. GeneDx had a return on equity of 20.22% and a net margin of 0.52%. GeneDx has set its FY 2025 guidance at EPS. Equities analysts expect that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on WGS. Wall Street Zen lowered GeneDx from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. Piper Sandler upped their target price on GeneDx from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, September 11th. Guggenheim reiterated a “buy” rating and issued a $170.00 price target (up previously from $115.00) on shares of GeneDx in a research report on Wednesday, October 29th. Wells Fargo & Company boosted their price objective on GeneDx from $95.00 to $140.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 4th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of GeneDx in a research note on Wednesday, October 8th. Seven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, GeneDx has a consensus rating of “Moderate Buy” and a consensus target price of $129.22.

Insider Transactions at GeneDx

In other GeneDx news, Director Jason Ryan sold 38,072 shares of the business’s stock in a transaction on Wednesday, August 27th. The shares were sold at an average price of $127.30, for a total value of $4,846,565.60. Following the sale, the director owned 103,284 shares of the company’s stock, valued at $13,148,053.20. The trade was a 26.93% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Casdin Capital, Llc sold 500,000 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $120.90, for a total value of $60,450,000.00. Following the completion of the transaction, the director directly owned 3,007,164 shares in the company, valued at $363,566,127.60. The trade was a 14.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 556,375 shares of company stock worth $67,569,247 over the last 90 days. Insiders own 29.60% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.